There has been some buying insider activity on VBI Vaccines, Inc. – Ordinary S (NASDAQ:VBIV) recently. Chief Medical Officer Francisco Diaz-mitoma disclosed the purchase of 3,000 shares. The shares were bought on August 21st for an average price of $3.17. The Chief Medical Officer now owns $9,510 of the stock per the Form 4 SEC filing. Sam Chawla, Director reported the purchase of 3,100,000 shares of (VBIV). The shares were purchased at an average price of $3.05. Chawla now owns $28,504,461 of the stock according to the SEC filing.
Steven Gillis, Director disclosed the purchase of 300,000 shares of VBIV stock. The shares were bought on October 30th for an average price of $3.05. Gillis now owns $9,229,474 of the stock per the Form 4 SEC filing. VBI Vaccines Inc., a commercial stage biopharmaceutical company, develops vaccine candidates and novel technology platforms in Israel and internationally. It develops products based on eVLP, a platform for the design of enveloped virus-like particle vaccines; and Lipid Particle Vaccines platform, a proprietary formulation and process that allows vaccines and biologics to preserve stability, potency, and safety. The company’s commercial stage product is Sci-B-Vac, a third-generation licensed hepatitis B vaccine for adults, children, and newborn infants. It is also involved in CMV vaccine program, which is in Phase I clinical trials for the prevention of cytomegalovirus infection; GBM immunotherapy program, a preclinical stage glioblastoma multiforme therapeutic vaccine candidate; and RSV vaccine program, a discovery stage novel respiratory syncytial virus vaccine candidate. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts..
The company is now unchanged from yesterday’s close of $3.44. Company shares are trading at $3.44 which is slightly below the 50 day moving average which is $3.77 and well below the 200 day moving average of $4.53. The 50 day moving average was down $-0.33 or -8.77% and the 200 day average moved down $-1.09.
In the last earnings report the EPS was $-0.87 and is projected to be $-0.89 for the current year with 40,229,000 shares outstanding. Analysts expect next quarter’s EPS to be $-0.24 and the next full year EPS is anticipated to be $-1.01.
Traders are feeling more bearish of late if you consider the uptick in short interest. The company saw a rise in short interest of 3.18% between September 29, 2017 and October 13, 2017. Short interest increased 28,757 over that period. With short interest at 934,310 and short average daily volume at 59,022, days to cover is 16.0 and the percentage of shorted shares was 0.04% on October 13.